Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynam...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 856657
Main Authors Busà, Rosalia, Sorrentino, Maria Concetta, Russelli, Giovanna, Amico, Giandomenico, Miceli, Vitale, Miele, Monica, Di Bella, Mariangela, Timoneri, Francesca, Gallo, Alessia, Zito, Giovanni, Di Carlo, Daniele, Conaldi, Pier Giulio, Bulati, Matteo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.03.2022
Subjects
B cells
BNT162 Vaccine
BNT162b2
booster dose
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunity, Cellular
Immunology
mRNA vaccine
mRNA Vaccines
RNA, Messenger - genetics
SARS-CoV-2
T cells
T-Lymphocytes
Vaccines, Synthetic
SARS-CoV-2
BNT162b2
B cells
T cells
booster dose
mRNA vaccine
Online AccessGet full text

Cover

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.
AbstractList Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.
Author Di Carlo, Daniele
Bulati, Matteo
Russelli, Giovanna
Timoneri, Francesca
Amico, Giandomenico
Zito, Giovanni
Busà, Rosalia
Sorrentino, Maria Concetta
Miceli, Vitale
Conaldi, Pier Giulio
Di Bella, Mariangela
Gallo, Alessia
Miele, Monica
AuthorAffiliation 1 Research Department, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT) , Palermo , Italy
3 Department of Regenerative Medicine, Ri.MED Foundation , Palermo , Italy
2 Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT) , Palermo , Italy
AuthorAffiliation_xml – name: 2 Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT) , Palermo , Italy
– name: 1 Research Department, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT) , Palermo , Italy
– name: 3 Department of Regenerative Medicine, Ri.MED Foundation , Palermo , Italy
Author_xml – sequence: 1
  givenname: Rosalia
  surname: Busà
  fullname: Busà, Rosalia
– sequence: 2
  givenname: Maria Concetta
  surname: Sorrentino
  fullname: Sorrentino, Maria Concetta
– sequence: 3
  givenname: Giovanna
  surname: Russelli
  fullname: Russelli, Giovanna
– sequence: 4
  givenname: Giandomenico
  surname: Amico
  fullname: Amico, Giandomenico
– sequence: 5
  givenname: Vitale
  surname: Miceli
  fullname: Miceli, Vitale
– sequence: 6
  givenname: Monica
  surname: Miele
  fullname: Miele, Monica
– sequence: 7
  givenname: Mariangela
  surname: Di Bella
  fullname: Di Bella, Mariangela
– sequence: 8
  givenname: Francesca
  surname: Timoneri
  fullname: Timoneri, Francesca
– sequence: 9
  givenname: Alessia
  surname: Gallo
  fullname: Gallo, Alessia
– sequence: 10
  givenname: Giovanni
  surname: Zito
  fullname: Zito, Giovanni
– sequence: 11
  givenname: Daniele
  surname: Di Carlo
  fullname: Di Carlo, Daniele
– sequence: 12
  givenname: Pier Giulio
  surname: Conaldi
  fullname: Conaldi, Pier Giulio
– sequence: 13
  givenname: Matteo
  surname: Bulati
  fullname: Bulati, Matteo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35401503$$D View this record in MEDLINE/PubMed
BookMark eNp1kt9u0zAUxiM0xMbYA3CDfMlNSmI7ccIFUlr-rNJUUFt2a504x5unJO5iZ1J5MV4Pt13RhoRvjnX8nd8n29_r6KS3PUbR2zSZMFaUH7TpunFCE0onRZbnmXgRnaV5zmNGKT95sj-NLpy7S8LiJWMsexWdsownaZaws-j3aoPKaKNI1XsTr6rlKp7Z65iSy7GzA7QE-obMsG3HFgYyD549kiW6je0dOlJpjwOZWut29bN1SKwm08U6zWlNyQ9tfuEQT41drFHdkm65qOIpOGzINShlevxI5r3HmwF86K382Gx3gKqBjTcPeDRcbQO_IzPbBV_svXsTvdTQOrx4rOfRz69f1rPL-Or7t_msuooVzzMfNwKQNbROWaZpKRjWwFPOc85A51iiEEzQIOKC1XUNjKusFAooskRrLBp2Hs0P3MbCndwMpoNhKy0YuW_Y4UbC4I1qUVLFUsg1JgoE16yGDADzIqVCgyiRBdanA2sz1h02KtwjPPAz6POT3tzKG_sgi7IQlKUB8P4RMNj7EZ2XnXEq_A30aEcnac5LmuXJXvruqddfk-PPB4E4CNRgnRtQS2U8eGN31qaVaSJ3MZP7mMldzOQhZmEy_WfyCP__zB8F9dha
CitedBy_id crossref_primary_10_1016_j_vaccine_2024_126494
crossref_primary_10_3390_bios13050539
crossref_primary_10_1016_j_ijid_2022_11_022
crossref_primary_10_3389_fimmu_2022_947320
crossref_primary_10_3389_fimmu_2022_947187
crossref_primary_10_3389_fimmu_2022_1012526
crossref_primary_10_3389_fimmu_2022_981350
crossref_primary_10_3389_fimmu_2023_1271353
crossref_primary_10_4103_bbrj_bbrj_213_22
crossref_primary_10_1016_j_diagmicrobio_2023_115948
crossref_primary_10_3343_alm_2023_43_3_290
crossref_primary_10_1016_j_jvacx_2024_100489
crossref_primary_10_1002_jmv_28360
crossref_primary_10_3390_microorganisms10081563
crossref_primary_10_3390_v14112541
crossref_primary_10_3390_v15051179
crossref_primary_10_1016_j_crmeth_2023_100690
crossref_primary_10_1093_ofid_ofac493
crossref_primary_10_3390_vaccines10122132
crossref_primary_10_1007_s15010_024_02225_w
crossref_primary_10_1016_j_heliyon_2024_e29116
crossref_primary_10_3390_ijms232315046
crossref_primary_10_3390_vaccines10122038
crossref_primary_10_3390_ijms26020681
crossref_primary_10_1002_jmv_28131
crossref_primary_10_3390_vaccines10081223
Cites_doi 10.3389/fimmu.2021.778679
10.1016/S1473-3099(21)00202-4
10.3390/cells10102541
10.1016/j.cmi.2021.05.042
10.1126/science.abf4063
10.20411/pai.v6i1.441
10.1016/j.bbrc.2021.07.037
10.1016/S0140-6736(21)02046-8
10.1016/j.xcrm.2021.100355
10.1126/sciimmunol.abf8891
10.3389/fcimb.2021.655896
10.1007/s40121-021-00521-8
10.3390/jdb9040058
10.1111/jcmm.17186
10.1016/j.medcli.2021.09.013
10.1016/j.chom.2022.01.003
10.1172/JCI157990
10.1080/22221751.2021.2022440
10.1126/sciimmunol.abl5344
10.1038/s41577-020-00479-7
10.1093/cid/ciab300
10.1126/scitranslmed.abd2223
10.1016/S0140-6736(21)02249-2
10.1126/sciimmunol.abi6950
10.1128/JCM.01950-19
10.1038/s41591-021-01548-7
10.1126/science.abb2762
10.3389/fimmu.2020.581807
ContentType Journal Article
Copyright Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati.
Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati
Copyright_xml – notice: Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati.
– notice: Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2022.856657
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ (Directory of Open Access Journals)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_2c31a6fe0ca74f3ba5aae68127fa79e3
PMC8987231
35401503
10_3389_fimmu_2022_856657
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-d7ae3d2b135f2973eba4144643af6e9e77372d7a473bbba34c597ca2e30ffe8d3
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:22:49 EDT 2025
Thu Aug 21 14:21:58 EDT 2025
Fri Jul 11 05:46:36 EDT 2025
Mon Jul 21 06:04:40 EDT 2025
Tue Jul 01 03:44:05 EDT 2025
Thu Apr 24 22:57:09 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords SARS-CoV-2
BNT162b2
B cells
T cells
booster dose
mRNA vaccine
Language English
License Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-d7ae3d2b135f2973eba4144643af6e9e77372d7a473bbba34c597ca2e30ffe8d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Suryaprakash Sambhara, Centers for Disease Control and Prevention (CDC), United States
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Reviewed by: Todd Bradley, Children’s Mercy Hospital, United States; Stephanie Longet, University of Oxford, United Kingdom
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.856657
PMID 35401503
PQID 2649256031
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_2c31a6fe0ca74f3ba5aae68127fa79e3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8987231
proquest_miscellaneous_2649256031
pubmed_primary_35401503
crossref_citationtrail_10_3389_fimmu_2022_856657
crossref_primary_10_3389_fimmu_2022_856657
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-24
PublicationDateYYYYMMDD 2022-03-24
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-24
  day: 24
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Chivu-Economescu (B4) 2022; 26
Ketas (B27) 2021; 6
Pollard (B24) 2021; 21
Martinez-Gallo (B17) 2021
Goel (B8) 2021; 6
Mazzoni (B7) 2022
Pedersen (B18) 2021; 27
Terreri (B23) 2022; 30
Hartley (B2) 2020; 5
Ai (B9) 2022; 11
Tarke (B21) 2021; 2
Demaret (B5) 2021; 12
Sterlin (B26) 2021; 13
Dan (B1) 2021; 371
Jaganathan (B16) 2021; 10
Thompson (B13) 2021; 21
Quinti (B25) 2021; 11
Barda (B11) 2021; 398
Krause (B6) 2021; 398
Sauer (B14) 2020; 11
Shafeque (B15) 2020; 58
Pouwels (B12) 2021; 27
Yan (B3) 2020; 367
Guerrera (B20) 2021; 6
Perez-Gomez (B10) 2021; 9
Piano Mortari (B28) 2021; 10
Takahama (B22) 2021; 571
Van Praet (B19) 2021; 73
References_xml – volume: 12
  year: 2021
  ident: B5
  article-title: Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.778679
– volume: 21
  year: 2021
  ident: B13
  article-title: SARS-CoV-2 Incidence and Vaccine Escape
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(21)00202-4
– volume: 10
  start-page: 1
  year: 2021
  ident: B28
  article-title: Highly Specific Memory B Cells Generation After the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
  publication-title: Cells
  doi: 10.3390/cells10102541
– volume: 27
  year: 2021
  ident: B18
  article-title: Negative SARS-CoV-2 Antibodies, T-Cell Response and Virus Neutralization Following Full Vaccination in a Renal Transplant Recipient: A Call for Vigilance
  publication-title: Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis
  doi: 10.1016/j.cmi.2021.05.042
– volume: 371
  start-page: 1
  year: 2021
  ident: B1
  article-title: Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection
  publication-title: Science
  doi: 10.1126/science.abf4063
– volume: 6
  year: 2021
  ident: B27
  article-title: Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
  publication-title: Pathog Immun
  doi: 10.20411/pai.v6i1.441
– volume: 571
  year: 2021
  ident: B22
  article-title: Simultaneous Monitoring Assay for T-Cell Receptor Stimulation-Dependent Activation of CD4 and CD8 T Cells Using Inducible Markers on the Cell Surface
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2021.07.037
– volume: 398
  year: 2021
  ident: B6
  article-title: Considerations in Boosting COVID-19 Vaccine Immune Responses
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02046-8
– volume: 2
  year: 2021
  ident: B21
  article-title: Impact of SARS-CoV-2 Variants on the Total CD4(+) and CD8(+) T Cell Reactivity in Infected or Vaccinated Individuals
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2021.100355
– volume: 5
  start-page: 1
  year: 2020
  ident: B2
  article-title: Rapid Generation of Durable B Cell Memory to SARS-CoV-2 Spike and Nucleocapsid Proteins in COVID-19 and Convalescence
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abf8891
– volume: 11
  year: 2021
  ident: B25
  article-title: IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
  publication-title: Front Cell Infect Microbiol
  doi: 10.3389/fcimb.2021.655896
– volume: 10
  year: 2021
  ident: B16
  article-title: Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals
  publication-title: Infect Dis Ther
  doi: 10.1007/s40121-021-00521-8
– volume: 9
  start-page: 1
  year: 2021
  ident: B10
  article-title: The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
  publication-title: J Dev Biol
  doi: 10.3390/jdb9040058
– volume: 26
  year: 2022
  ident: B4
  article-title: Kinetics and Persistence of Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccine in Healthcare Workers With or Without Prior COVID-19
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.17186
– year: 2021
  ident: B17
  article-title: Commercialized Kits to Assess T-Cell Responses Against SARS-CoV-2 S Peptides. A Pilot Study in Health Care Workers
  publication-title: Med Clin
  doi: 10.1016/j.medcli.2021.09.013
– volume: 30
  year: 2022
  ident: B23
  article-title: Persistent B Cell Memory After SARS-CoV-2 Vaccination is Functional During Breakthrough Infections
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2022.01.003
– year: 2022
  ident: B7
  article-title: SARS-CoV-2 Infection and Vaccination Trigger Long-Lived B and CD4+ T Lymphocytes: Implications for Booster Strategies
  publication-title: J Clin Invest
  doi: 10.1172/JCI157990
– volume: 11
  year: 2022
  ident: B9
  article-title: Omicron Variant Showed Lower Neutralizing Sensitivity Than Other SARS-CoV-2 Variants to Immune Sera Elicited by Vaccines After Boost
  publication-title: Emerg Microbes Infect
  doi: 10.1080/22221751.2021.2022440
– volume: 6
  year: 2021
  ident: B20
  article-title: BNT162b2 Vaccination Induces Durable SARS-CoV-2-Specific T Cells With a Stem Cell Memory Phenotype
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abl5344
– volume: 21
  start-page: 83
  year: 2021
  ident: B24
  article-title: A Guide to Vaccinology: From Basic Principles to New Developments
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-00479-7
– volume: 73
  year: 2021
  ident: B19
  article-title: Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
  publication-title: Clin Infect Dis: Off Publ Infect Dis Soc Am
  doi: 10.1093/cid/ciab300
– volume: 13
  start-page: 1
  year: 2021
  ident: B26
  article-title: IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2
  publication-title: Sci Trans Med
  doi: 10.1126/scitranslmed.abd2223
– volume: 398
  year: 2021
  ident: B11
  article-title: Effectiveness of a Third Dose of the BNT162b2 mRNA COVID-19 Vaccine for Preventing Severe Outcomes in Israel: An Observational Study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02249-2
– volume: 6
  start-page: 1
  year: 2021
  ident: B8
  article-title: Distinct Antibody and Memory B Cell Responses in SARS-CoV-2 Naive and Recovered Individuals Following mRNA Vaccination
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abi6950
– volume: 58
  start-page: 1
  year: 2020
  ident: B15
  article-title: Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01950-19
– volume: 27
  year: 2021
  ident: B12
  article-title: Effect of Delta Variant on Viral Burden and Vaccine Effectiveness Against New SARS-CoV-2 Infections in the UK
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01548-7
– volume: 367
  year: 2020
  ident: B3
  article-title: Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2
  publication-title: Science
  doi: 10.1126/science.abb2762
– volume: 11
  year: 2020
  ident: B14
  article-title: An Effective COVID-19 Vaccine Needs to Engage T Cells
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.581807
SSID ssj0000493335
Score 2.4380643
Snippet Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 856657
SubjectTerms B cells
BNT162 Vaccine
BNT162b2
booster dose
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunity, Cellular
Immunology
mRNA vaccine
mRNA Vaccines
RNA, Messenger - genetics
SARS-CoV-2
T cells
T-Lymphocytes
Vaccines, Synthetic
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSkhcEG8KCxokTkhmEzuJE25pYbWLRIW6D-0tsh1bG9Qmqz4Ou3-Mv8dM3FYtQnDhmtix5Zl4vvGMv2HsfSxMFtk85Wjd0UGxIuZG5ZZbj9jBeYUbIN1G_jbOTi6Sr1fp1U6pL8oJC_TAYeGOhJWxzryLrFaJl0anWjsizVJeq8L1PJ9o83acqR8B90op0xDGRC-sOPLNbLZCf1CIj3lK4YY9Q9Tz9f8JZP6eK7ljfI4fsYdr1AhlmO1jds-1T9j9UEfy9in72VeR942Fsl02_KycnPFRd8kFoLToCj7otoaRm04p6RRO6U6Ig0lIj3ULKKlQOAw7uvAxh8_dwkHnYTg-jzNhBHz3zZ2bcxxuTCfxMJuMSz5E81fDpbYUmf8EpxvaiRooNfGWPlDW-oZ2082AgR0daAvqWkrgeMYujr-cj074uiIDt0mWLnmttJO1MLFMPRW9ckYn5FAmUvvMFU5R0RtslChpjNEyseivWC2cjLx3eS2fs4MWR3jJoDA-9TpytVSIyLLUxEUudIaW1CSEygYs2oinsmu6cqqaMa3QbSGJVr1EK5JoFSQ6YB-2XW4CV8ffGg9J5tuGRLPdP0Dlq9bKV_1L-Qbs3UZjKvwtKdaiW9etFhXizILQpIwH7EXQoO1QdNSGOBx7qz3d2pvL_pu2ue6pv_MiV4jIX_2Pyb9mD2g9KKFOJIfsYDlfuTeIsJbmbf8z_QI4XyZu
  priority: 102
  providerName: Directory of Open Access Journals
Title Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
URI https://www.ncbi.nlm.nih.gov/pubmed/35401503
https://www.proquest.com/docview/2649256031
https://pubmed.ncbi.nlm.nih.gov/PMC8987231
https://doaj.org/article/2c31a6fe0ca74f3ba5aae68127fa79e3
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfGEBIviO91wGQknpA8EjuJEySE0sLYkFahbp36FtmODUVtsqWtRPnH-Pe4y0dFUcUTL3lI7Njy2b7f-c73I-SVz3XkmThkoN3BQDHcZ1rGhhkH2ME6CRsg3kY-H0an4-DzJJzskY7eqh3AxU7TDvmkxtXs-MfN-j0s-HdocYK-feOm8_kKTD3Oj-MQPQm3yG1QTBIJDc5btP-9AcNCiLDxbe6uuaWd6iT-u5Dn3wGUf2ikk_vkXgsladrI_gHZs8VDcqchl1w_Ir9qank3NTQtllN2kY4u2KC8YpyCCPFePlVFTgd2NsNIVHqGF0UsHTUxs3ZBU2QPp_0Sb4FU9EO5sLR0tD-89COuOf3ipj9txaC5IR7P0_lomLI-6MScXimD7vq39KzLRZFTjFdc4w_SXF3jFts12KRMp7gvlQVGdTwm45OPl4NT1tI0MBNE4ZLlUlmRc-2L0CETltUqQCszEMpFNrESmXCgUCCF1lqJwIARYxS3wnPOxrl4QvYLaOGA0ES70CnP5kICTItC7ScxVxGoVx0gVOsRrxNPZtoc5kilMcvAlkGJZrVEM5Ro1ki0R15vqlw3CTz-VbiPMt8UxNzb9Yuy-pq1SznjRvgqctYzSgZOaBUqZTGNm3RKJlb0yMtuxmSwVtEBowpbrhYZgM8EIabwe-RpM4M2TeH5G4BzqC235tZWX7a_FNNvdT7wOIklwPTD_9H5Z-QujgdG2fHgOdlfViv7AmDXUh_VxxXw_DTxj-qF9Rt13TAy
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Specific+Anti-SARS-CoV-2+Humoral+and+Cellular+Immune+Responses+After+Booster+Dose+of+BNT162b2+Pfizer-BioNTech+mRNA-Based+Vaccine%3A+Integrated+Study+of+Adaptive+Immune+System+Components&rft.jtitle=Frontiers+in+immunology&rft.au=Rosalia+Bus%C3%A0&rft.au=Maria+Concetta+Sorrentino&rft.au=Giovanna+Russelli&rft.au=Giandomenico+Amico&rft.date=2022-03-24&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.856657&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2c31a6fe0ca74f3ba5aae68127fa79e3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon